A Randomized, Muticenter Double-blind Phase III Study of Neoadjuvant Pyrotinib Plus Trastuzumab and Docetaxel Compared With Placebo Plus Trastuzumab and Docetaxel in Women With HER2 Positive Early Stage or Locally Advanced Breast Cancer
Phase of Trial: Phase III
Latest Information Update: 26 Jul 2018
Price : $35 *
At a glance
- Drugs Docetaxel (Primary) ; Pyrotinib (Primary) ; Trastuzumab (Primary)
- Indications Advanced breast cancer
- Focus Registrational; Therapeutic Use
- Sponsors Jiangsu Hengrui Medicine Co.
- 23 Jul 2018 New trial record
- 17 Jul 2018 Status changed from not yet recruiting to recruiting.